Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide
MWN-AI** Summary
Palatin Technologies, Inc. recently announced promising results from its Phase 2 obesity study, BMT-801, which evaluated the appetite suppression effects of the melanocortin 4 receptor (MC4R) agonist, bremelanotide, both alone and in combination with tirzepatide, a glucagon-like peptide-1 (GLP-1) agonist. The study indicated significant improvements in appetite suppression, satiety, and fullness across all treatment arms, particularly highlighting that bremelanotide matched or surpassed tirzepatide regarding appetite control.
The trial aimed to explore whether low-dose bremelanotide could enhance long-term weight maintenance after the cessation of GLP-1 therapies—a common challenge in obesity management. Results showed that, while over 50% of weight loss was typically regained within two weeks after stopping tirzepatide, patients switching to low-dose bremelanotide after initial weight loss maintained their weight without significant rebound. This outcome suggests a potential role for MC4R agonists in supporting sustained weight management.
Patient-reported outcomes using a validated appetite questionnaire revealed substantial increases in appetite suppression (71% for both bremelanotide and tirzepatide) and fullness (79% for bremelanotide alone). Furthermore, the co-administration of bremelanotide and tirzepatide demonstrated notable effects on satiety.
These encouraging findings prompt further analysis of secondary endpoints relating to body composition and BMI, with additional results expected to be presented at forthcoming medical conferences. Palatin is advancing its pipeline, including next-generation MC4R agonists, aimed at broader obesity indications, with expectations for initial clinical data by the first half of 2026. The outcomes from this study may bolster Palatin's position in the obesity treatment landscape.
MWN-AI** Analysis
Palatin Technologies, Inc. (NYSE American: PTN) has recently announced promising results from its Phase 2 BMT-801 obesity study, demonstrating significant appetite suppression efficacy via its MC4R agonist, bremelanotide, co-administered with tirzepatide. The study reveals that both treatments, individually and in combination, markedly improved appetite metrics, suggesting a potential breakthrough in obesity management.
Investors should take note of several key points from the study. Firstly, the ability of low-dose bremelanotide to reduce appetite rebound following the cessation of tirzepatide therapy indicates its potential to provide a sustainable weight management solution. Traditionally, weight regain has been a significant challenge post-treatment with existing obesity medications, making Palatin’s findings noteworthy and potentially disruptive in the obesity therapeutics market.
Furthermore, the data showing that bremelanotide can match tirzepatide in appetite suppression—without the adverse effects of rebound weight gain—positions Palatin favorably against larger competitors in the obesity drug space, particularly as healthcare costs associated with obesity continue to rise. This competitive edge could translate to increased market share and influence commercial partnerships moving forward.
However, while the results are encouraging, investors should remain cautious. The company's future depends not only on the successful completion of upcoming clinical trials and regulatory approvals but also on managing the competitive landscape within the obesity treatment segment. Monitoring the presentation of full study results and subsequent analyses will be crucial as they will provide additional insights into the therapeutic potential of Palatin’s pipeline.
For those considering investing, Palatin Technologies appears poised for potential growth given its innovative approach to obesity treatment, but inherent risks related to clinical trial outcomes and market acceptance remain. Therefore, a watchful eye on the company's developments and the broader biotech market trends is recommended.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
- Co-administered bremelanotide + tirzepatide, bremelanotide alone, and tirzepatide alone arms showed improvement in appetite suppression, fullness, and satiety
- Bremelanotide matched or exceeded tirzepatide in appetite suppression
- Low-dose bremelanotide helped prevent appetite rebound after tirzepatide cessation
CRANBURY, N.J. , April 17, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, announced positive appetite suppression results from its BMT-801 Phase 2 obesity study. The study included a co-administered melanocortin 4 receptor (MC4R) agonist bremelanotide plus glucagon like peptide-1/gastric inhibitory polypeptide ( GLP-1 /GIP) tirzepatide arm, bremelanotide alone, and tirzepatide alone arms.
"One of the important research questions that the study was designed to answer was whether a low- dose of an MC4R agonist could support long-term weight loss maintenance. We're excited with the results, which demonstrated that low-dose bremelanotide matched tirzepatide in appetite suppression, a compelling outcome," said Carl Spana , Ph.D., President and CEO of Palatin. "Just as importantly, low-dose bremelanotide significantly reduced the appetite rebound typically observed after stopping GLP-1 /GIP therapy—one of the major hurdles in sustained obesity management."
Key Results – Appetite Suppression (Patient-Reported Outcomes)
Using a validated daily appetite questionnaire, the study showed that patients receiving co-administered bremelanotide + tirzepatide, tirzepatide alone, and bremelanotide alone, experienced significant improvements in appetite suppression, fullness, and satiety. Patients who transitioned to placebo after initial weight loss on tirzepatide showed no improvement for appetite suppression.
- Overall appetite suppression
- Bremelanotide + tirzepatide: 71% increase
- Tirzepatide only: 73% increase
- Bremelanotide only: 71% increase
- "How full do you feel (fullness)?"
- Bremelanotide + tirzepatide: 65% increase
- Tirzepatide only: 62% increase
- Bremelanotide only: 79% increase
- "How satisfied do you feel (satiety)?"
- Bremelanotide + tirzepatide: 56% increase
- Tirzepatide only: 56% increase
- Bremelanotide only: 68% increase
Consistent with known effects of GLP-1 /GIP therapy, over 50% of lost weight was regained within two weeks of stopping treatment in both the tirzepatide and co-administration arms of the study. In contrast, patients who transitioned to low-dose bremelanotide after initial weight loss on tirzepatide maintained their weight without any significant regain, underscoring the potential of MC4R agonists as a valuable therapy for long-term weight maintenance.
Topline results from the BMT-801 Phase 2 trial, released last month, demonstrated statistically significant weight loss with bremelanotide co-administered with tirzepatide versus placebo over an 8-week treatment period. Further analysis of secondary and exploratory endpoints—including body composition and BMI—is ongoing.
Full study results will be submitted for presentation at an upcoming medical conference. Additional trial details are available at clinicaltrials.gov under identifier NCT06565611 .
Pipeline Development
Palatin continues to advance its next-generation MC4R agonists, including long-acting peptides and oral small molecules, targeting broad obesity indications—including monotherapy and combination regimens with incretin-based therapies, as well as rare and genetic obesity disorders such as hypothalamic obesity. IND filings are anticipated by end of Q4 2025, with initial clinical data expected in the first half of 2026.
About Melanocortin-4 Receptor Agonists Effect on Obesity
Genetic analysis has identified the melanocortin-4 receptor (MC4R) of the paraventricular nucleus of the hypothalamus as playing a central role in appetite regulation. Genetic mutations that inhibit signaling in the MC4R pathway lead to hyperphagia, decreased energy expenditure and early-onset obesity; such mutations have been identified as the cause of several rare genetic obesity disorders. Agouti-related peptide is an endogenous antagonist of the MC4R that works with neuropeptide Y to stimulate appetite, whereas MC4R agonists such as ?- and ?-melanocyte-stimulating hormone promote satiety. MC4R agonism represents an attractive target for potential obesity treatments.
About Melanocortin Receptor Agonists
The melanocortin receptor ("MCR") system has effects on inflammation, immune system responses, metabolism, food intake, and sexual function. There are five melanocortin receptors, MC1R through MC5R. Modulation of these receptors, through use of receptor-specific agonists, which activate receptor function, or receptor-specific antagonists, which block receptor function, can have medically significant pharmacological effects.
About Palatin
Palatin is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor systems, with targeted, receptor-specific product candidates for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin's website at www.Palatin.com and follow Palatin on Twitter at @PalatinTech.
Forward-looking Statements
Statements in this press release that are not historical facts, including statements about future expectations of Palatin Technologies, Inc., such as statements about Palatin products in development, clinical trial results, potential actions by regulatory agencies, regulatory plans, development programs, proposed indications for product candidates, and market potential for product candidates are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. Palatin intends that such forward-looking statements be subject to the safe harbors created thereby. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause Palatin's actual results to be materially different from its historical results or from any results expressed or implied by such forward-looking statements. Palatin's actual results may differ materially from those discussed in the forward-looking statements for reasons including, but not limited to, results of clinical trials, regulatory actions by the FDA and other regulatory and the need for regulatory approvals, Palatin's ability to fund development of its technology and establish and successfully complete clinical trials, the length of time and cost required to complete clinical trials and submit applications for regulatory approvals, products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies, commercial acceptance of Palatin's products, and other factors discussed in Palatin's periodic filings with the Securities and Exchange Commission. Palatin is not responsible for updating events that occur after the date of this press release.
SOURCE Palatin Technologies, Inc.
FAQ**
How do the appetite suppression results of Palatin Technologies Inc. PTN's bremelanotide compare with those of tirzepatide in the context of the Phase 2 obesity study?
What implications do the findings regarding low-dose bremelanotide's ability to prevent appetite rebound have for long-term weight management in patients treated by Palatin Technologies Inc. PTN?
Can Palatin Technologies Inc. PTN discuss the potential market opportunities for its MC4R agonists, including bremelanotide, based on the Phase 2 trial outcomes?
What are the next steps for Palatin Technologies Inc. PTN regarding further development of MCagonists after the promising results from the BMT-801 Phase 2 study?
**MWN-AI FAQ is based on asking OpenAI questions about Palatin Technologies Inc. (NYSE: PTN).
NASDAQ: PTN
PTN Trading
1.99% G/L:
$22.54 Last:
6,973 Volume:
$21.35 Open:
